Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Reglitazar
Cat. No.:
0225LY-0826
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Reglitazar is a dual agonist targeting both PPAR-alpha and PPAR-gamma, utilized primarily in diabetes research.
Synonym:
JTT501; PNU-182716; PNU182716; PNU-716; JTT-501; 170861-63-9; Reglitazar [INN]; 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione; P9UTN18JVV; JTT-501.BETA.; JT-501; 3,5-Isoxazolidinedione, 4-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]isoxazolidine-3,5-dione; 4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)isoxazolidine-3,5-dione; JTT 501beta
CAS No.:
170861-63-9
Compound CID:
154000
Formula:
C22H20N2O5
Formula Weight:
392.4
Specification
Relative Density:
1.31 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Reglitazar can be used in diabetes studies to explore its role as a dual agonist of PPAR alpha and gamma receptors.
Library Information
Target:
PPAR
Receptor:
PPARα ; PPARγ
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-11
Plate Location:
f5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
